Use of bi-aryl meta-pyrimidine inhibitors of kinases
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Mar 13, 2012
Grant Date -
Nov 19, 2009
app pub date -
Oct 14, 2008
filing date -
Nov 1, 2005
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The invention provides methods of treating a disease selected from systemic sclerosis, rheumatoid arthritis, mastocytosis, and chronic eosinophilic leukemia comprising administering biaryl meta-pyrimidine compounds having the general structure (A) to a subject in need thereof. The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the JAK kinase family, and various other specific receptor and non-receptor kinases.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully